Floatz logo

Lactobacillus Rhamnosus Gg

Urinary Tract Infection

Medstar Health Research InstituteUNKNOWNEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Urinary Tract Infection cohort.

Asset / SponsorPhaseRating
Normal Human Serum Albumin
EASL - CLIF Consortium
Phase 4BB
Cranberry
Rennes University Hospital
Phase 3B
Allocetra-Ots
Enlivex Therapeutics Ltd.
Phase 2CCC
Cotrimoxazole
Indonesia University
Phase 2CC
Gentamicin
Medstar Health Research Institute
Early Phase 1C

View all 9 →

Same molecule, other indications

Lactobacillus Rhamnosus Gg is also rated in:

spina bifidaActive
C
Indicative · Early Phase 1
39 / 100
View asset →
spinal cord injuryActive
C
Indicative · Early Phase 1
38 / 100
View asset →
multiple sclerosisActive
C
Indicative · Early Phase 1
34 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →